Galectin-3 in Heart Failure An Update of the Last 3 Years

被引:81
|
作者
Gehlken, Carolin [1 ]
Suthahar, Navin [1 ]
Meijers, Wouter C. [1 ]
de Boer, Rudolf A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands
关键词
Galectin-3; Heart failure; Fibrosis; inhibitor; Biomarker; Prognosis; MODIFIED CITRUS PECTIN; PROGNOSTIC VALUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL FIBROSIS; PREDICTIVE-VALUE; PERFORMANCE-CHARACTERISTICS; RISK STRATIFICATION; SERIAL MEASUREMENTS; CARDIAC BIOMARKERS; EUROPEAN-SOCIETY;
D O I
10.1016/j.hfc.2017.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases.
引用
收藏
页码:75 / +
页数:19
相关论文
共 50 条
  • [1] Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
    Suthahar, Navin
    Meijers, Wouter C.
    Sillje, Herman H. W.
    Ho, Jennifer E.
    Liu, Fu-Tong
    de Boer, Rudolf A.
    THERANOSTICS, 2018, 8 (03): : 593 - 609
  • [2] The involvement of galectin-3 in heart failure
    Kalan, Maria
    Witczak, Agnieszka
    Mosiewicz, Jerzy
    Donica, Helena
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2015, 69 : 1107 - 1113
  • [3] The role of galectin-3 in heart failure
    Ricupati, F. Federica
    Novo, S. Salvatore
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 220 - 220
  • [4] Galectin-3 in cardiac remodeling and heart failure
    De Boer R.A.
    Yu L.
    Van Veldhuisen D.J.
    Current Heart Failure Reports, 2010, 7 (1) : 1 - 8
  • [5] Galectin-3 in different phenotypes of heart failure
    Hage, C. Camilla
    Bergman, A-C
    Estonius, M.
    Donal, E.
    Linde, C.
    Daubert, J-C
    Lund, L. H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 492 - 493
  • [6] The role of galectin-3 in heart failure and cardiovascular disease
    Zhong, Xiao
    Qian, Xiaoqian
    Chen, Guangping
    Song, Xiang
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2019, 46 (03): : 197 - 203
  • [7] Galectin-3: A Modifiable Risk Factor in Heart Failure
    de Boer, Rudolf A.
    van der Velde, A. Rogier
    Mueller, Christian
    van Veldhuisen, Dirk J.
    Anker, Stefan D.
    Peacock, W. Frank
    Adams, Kirkwood F.
    Maisel, Alan
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (03) : 237 - 246
  • [8] Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure
    Rudolf A. de Boer
    Lili Yu
    Dirk J. van Veldhuisen
    Current Heart Failure Reports, 2012, 9 (3) : 163 - 163
  • [9] Galectin-3: A Modifiable Risk Factor in Heart Failure
    Rudolf A. de Boer
    A. Rogier van der Velde
    Christian Mueller
    Dirk J. van Veldhuisen
    Stefan D. Anker
    W. Frank Peacock
    Kirkwood F. Adams
    Alan Maisel
    Cardiovascular Drugs and Therapy, 2014, 28 : 237 - 246
  • [10] Personalizing biomarker strategies in heart failure with galectin-3
    Sherwi, Nasser
    Merali, Shermin
    Wong, Kenneth
    FUTURE CARDIOLOGY, 2012, 8 (06) : 885 - 894